BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 05/15/23

BrainStorm Cell Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Biologics License Application for NurOwn® for the treatment of ALS to be subject of an upcoming FDA Advisory Committee Meeting Conference call and webca...

BrainStorm to Announce First Quarter 2023 Financial Results and Provide a Corporate Update PR Newswire NEW YORK , May 9, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative disease...

BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer PR Newswire Dr. Taylor has extensive biopharma industry expertise in neurodegenerative disease and experience leading drug laun...

2023-03-31 12:58:15 ET Gainers: Y-mAbs Therapeutics ( YMAB ) +61% . Burford Capital Limited ( BUR ) +42% . Pulse Biosciences ( PLSE ) +29% . Brainstorm Cell Therapeutics ( BCLI ) +29% . Bionomics Limited ( BNOX ) +25% . Fisca...

2023-03-30 11:36:09 ET Brainstorm Cell Therapeutics Inc. (BCLI) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Michael Wood - LifeSci Advisors Chaim Lebovits - President and Chief Executive Officer Stacy Lindborg - Co-Chief Execut...

2023-03-30 11:29:30 ET Brainstorm Cell Therapeutics ( NASDAQ: BCLI ) stock fell ~10% on Thursday amid the company's FY22 results after soaring ~50% in the past three days. The company's shares started surging since Monday after it said that the FDA is expecte...

2023-03-30 10:02:34 ET Gainers: SCYNEXIS ( SCYX ) +61% . Palisade Bio ( PALI ) +33% . Biophytis ( BPTS ) +10% . RenovoRx ( RNXT ) +9% . VYNE Therapeutics ( VYNE ) +9% . Losers: AngioDynamics ( ANGO ) -28% . ...

2023-03-30 09:16:18 ET Summary BrainStorm just announced that it has secured an FDA advisory committee vote for treatment candidate NurOwn for the treatment of ALS. NurOwn’s results on biomarker NfL have actually been remarkable good, outperforming Biogen’s/Ionis...

2023-03-30 07:06:47 ET BrainStorm Cell Therapeutics press release ( NASDAQ: BCLI ): Q4 GAAP EPS of -$0.66 misses by $0.52 . Cash, cash equivalents, and short-term bank deposits were approximately $3 million as of December 31, 2022, compared to $22 million as of Decembe...

BrainStorm Cell Therapeutics Announces Full Year 2022 Financial Results and Provides a Corporate Update PR Newswire Biologics License Application for NurOwn® for the treatment of ALS to be discussed in an upcoming FDA Advisory Committee Meeting Conference call and...